Literature DB >> 23826785

ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets.

Meike Vogler1, David Dinsdale, Martin J S Dyer, Gerald M Cohen.   

Abstract

Entities:  

Keywords:  ABT-199; BCL-XL (BCL2L1); BCL2; apoptosis; chronic lymphocytic leukaemia

Mesh：

Substances：

Year:  2013        PMID： 23826785     DOI： 10.1111/bjh.12457

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  37 in total

Review 1.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

2.  Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.

Authors:  Xiaojia Niu; Jianyun Zhao; Jun Ma; Chengzhi Xie; Holly Edwards; Guan Wang; J Timothy Caldwell; Shengyan Xiang; Xiaohong Zhang; Roland Chu; Zhihong J Wang; Hai Lin; Jeffrey W Taub; Yubin Ge
Journal:  Clin Cancer Res       Date:  2016-04-21       Impact factor: 12.531

Review 3.  Many players in BCL-2 family affairs.

Authors:  Tudor Moldoveanu; Ariele Viacava Follis; Richard W Kriwacki; Douglas R Green
Journal:  Trends Biochem Sci       Date:  2014-02-03       Impact factor: 13.807

Review 4.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

Review 5.  Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.

Authors:  Joel D Leverson; Deepak Sampath; Andrew J Souers; Saul H Rosenberg; Wayne J Fairbrother; Martine Amiot; Marina Konopleva; Anthony Letai
Journal:  Cancer Discov       Date:  2017-11-16       Impact factor: 39.397

Review 6.  Venetoclax: First Global Approval.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2016-06       Impact factor: 9.546

Review 7.  The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2016-07-08

8.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Authors:  Marina Konopleva; Daniel A Pollyea; Jalaja Potluri; Brenda Chyla; Leah Hogdal; Todd Busman; Evelyn McKeegan; Ahmed Hamed Salem; Ming Zhu; Justin L Ricker; William Blum; Courtney D DiNardo; Tapan Kadia; Martin Dunbar; Rachel Kirby; Nancy Falotico; Joel Leverson; Rod Humerickhouse; Mack Mabry; Richard Stone; Hagop Kantarjian; Anthony Letai
Journal:  Cancer Discov       Date:  2016-08-12       Impact factor: 39.397

9.  Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.

Authors:  Shao Xie; Hui Jiang; Xiao-Wen Zhai; Fan Wei; Shu-Dong Wang; Jian Ding; Yi Chen
Journal:  Acta Pharmacol Sin       Date:  2016-08-29       Impact factor: 6.150

Review 10.  Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.

Authors:  Lesley J Scott
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.